Press Releases

VYNE Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

September, 06 2022

BRIDGEWATER, N.J., Sept. 06, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer of VYNE, is scheduled to participate at the H.C. Wainwright 24th Annual Global Investment Conference (Hybrid) on September 13, 2022. Management will also be available for one-on-one meetings with investors. H.C. Wainwright 24th Annual Global Investment Conference – Presentation Details Date: Tuesday, September 13, 2022 Time: 12:30 p.m. ET Format: Company Presentation Presenter: David Domzalski, President and Chief…

Read More

VYNE Therapeutics Reports Second Quarter 2022 Financial Results

August, 12 2022

BRIDGEWATER, N.J., Aug. 12, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced financial results for the three and six months ended June 30, 2022. “We believe our BET inhibitor platform holds unique and significant potential to address several immuno-inflammatory diseases, and we look forward to communicating our future plans following our review of our pipeline and prioritization of activities,” said David Domzalski, President and Chief Executive Officer of VYNE. Financial Performance(in thousands) Three Months Ended June 30,   Six…

Read More

VYNE Therapeutics Announces Results from its Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis

August, 10 2022

BRIDGEWATER, N.J., Aug. 10, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced results from the Phase 2a segment of a Phase 1b/2a clinical trial evaluating FMX114 for the treatment of mild-to-moderate atopic dermatitis (“AD”). Study VY2021-01 did not meet its primary endpoint based on the absolute and percent change relative to baseline in the Atopic Dermatitis Severity Index (“ADSI”). The Phase 2a study of FMX114 enrolled 21 patients and was designed to evaluate four weeks of FMX114 treatment…

Read More

VYNE Therapeutics to Present at the B&T Cell-Mediated Autoimmune Disease Drug Development Conference

July, 19 2022

BRIDGEWATER, N.J., July 19, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that Iain Stuart, Ph.D., Chief Scientific Officer of VYNE, will be presenting at the B&T Cell-Mediated Autoimmune Disease Drug Development Conference (in-person) on July 27, 2022. B&T Cell-Mediated Autoimmune Disease Drug Development Conference (in-person) – Presentation Details Presentation Date: July 27, 2022 Presenter: Iain Stuart, Ph.D., Chief Scientific Officer of VYNE Presentation Track: Harnessing Autoantibody Signatures and Mapping Out the B&T Cell-Mediated Autoimmune Disease Landscape Presentation…

Read More

VYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis

June, 17 2022

BRIDGEWATER, N.J., June 17, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced the completion of enrollment in the Phase 2a study of FMX114 for the treatment of mild-to-moderate atopic dermatitis (“AD”). FMX114 is VYNE’s proprietary investigational combination gel formulation of tofacitinib and fingolimod, which has been designed to address both the source and cause of inflammation in AD. In April 2022, VYNE reported positive efficacy data from the Phase 1b segment of the trial, demonstrating that treatment with…

Read More

VYNE Therapeutics to Present at HC Wainwright & Co. Global Investment Conference

May, 18 2022

BRIDGEWATER, N.J., May 18, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer, and Dr. Iain Stuart, Chief Scientific Officer, will present at the HC Wainwright & Co. Global Investment Conference on May 25, 2022. Management will also be available for one-on-one meetings with investors. HC Wainwright & Co. Global Investment Conference – Presentation Details Date: Wednesday, May 25, 2022 Time: 9:00 a.m. ET Webcast Link: https://journey.ct.events/view/f49ba6f9-4835-4fb5-9a1c-0c341c71da26 *a replay will be…

Read More